LI
Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
$4.07 +9.61% (+$0.36)
1M -22.06%
Market Cap $4.89M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 16.26x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 225.12%
ROA 367.93%
Asset turnover 0.00x
Debt
10 /100
High Debt/Equity 4.80x
Current ratio 1.12x
Int. coverage -291.82x
Stability
37 /100
Moderate Beta 0.71x
EPS volatility 79.63%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LIMN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chris Kim
Employees
1
Headquarters
Cerritos